Δ8-THC shares the same molecular formula as delta-9-THC (C₂₁H₃₀O₂) but differs by the location of a carbon–carbon double bond: it sits between C8 and C9, rather than between C9 and C10. This seemingly small shift alters the molecule's three-dimensional geometry and is thought to influence how it fits at cannabinoid binding sites, though the pharmacological significance of this difference is still being characterised in the published literature.
Because it occurs at very low concentrations in the cannabis plant, commercial Δ8-THC is typically produced semi-synthetically by isomerising cannabidiol (CBD) under acidic conditions , a process that can generate a range of uncharacterised by-products. In Australia, both naturally derived and synthetically produced Δ8-THC are captured under the definition of tetrahydrocannabinols in the Poisons Standard (the current Therapeutic Goods (Poisons Standard , Cannabis and Hemp) Order). It is classified as a Schedule 9 Prohibited Substance except where it meets the specific criteria for a lower schedule , criteria that apply to a narrow set of approved therapeutic preparations only.
At the receptor level, Δ8-THC acts as a partial agonist at both CB1 and CB2 receptors of the endocannabinoid system, in a broadly comparable manner to Δ9-THC, though published binding-affinity data generally indicate a lower potency at CB1. Early preclinical research conducted from the 1970s onward (including work cited by the US National Cancer Institute) examined its pharmacological profile in animal models. Human clinical data remain sparse; the bulk of available evidence comes from in vitro studies and small, older trials, and no regulatory body; including the Therapeutic Goods Administration (TGA), has approved a Δ8-THC-specific therapeutic product.
Internationally, regulatory scrutiny of Δ8-THC has increased markedly since 2020, driven largely by the proliferation of hemp-derived products in unregulated markets. The US FDA issued a consumer advisory in 2022 noting safety concerns around the semi-synthetic conversion process and reported adverse events. In Australia, the TGA's scheduling position means any supply outside an approved pathway is unlawful under the Therapeutic Goods Act 1989.
Sources: